{
    "clinical_study": {
        "@rank": "149558", 
        "arm_group": [
            {
                "arm_group_label": "Observation arm", 
                "arm_group_type": "No Intervention", 
                "description": "Subjects will be monitored closely for disease progression, however will receive no intervention."
            }, 
            {
                "arm_group_label": "Peginterferon alfa-2a", 
                "arm_group_type": "Experimental", 
                "description": "Peginterferon alfa-2a will be administered at a dose of 50 micrograms once a week for up to 3 years."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to look at the effectiveness of giving patients who have been\n      newly diagnosed with untreated early stage primary myelofibrosis (PMF) a study drug called\n      PEGINTRON (also known as pegylated interferon alfa 2b). This intervention will be compared\n      to the widely employed \"watch and wait\" (best supportive care) approach for early stage PMF,\n      in which patients are followed closely and treatment initiated only if the disease\n      progresses."
        }, 
        "brief_title": "Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelofibrosis", 
        "condition_browse": {
            "mesh_term": "Primary Myelofibrosis"
        }, 
        "detailed_description": {
            "textblock": "Subjects will be randomized into one of the study groups:  one in which subjects get treated\n      with PEGINTRON and the other in which subjects are closely followed and get best supportive\n      care until disease progression (the presently accepted standard approach for early disease).\n      Subjects on the observation arm will be carefully monitored for clinical or laboratory\n      progression of disease during scheduled study visits. However, they will not be treated with\n      an active drug like Interferon alfa or others such as Hydroxyurea, Revlimid, Thalidomide,\n      Pomalidomide, and the newly approved JAK2 inhibitor Ruxolitinib (Jakafi). If their disease\n      progresses, they will be eligible for cross-over into the treatment arm with PEGINTRON.\n      Subjects randomized to the treatment arm will receive PEGINTRON once weekly."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Patients must meet laboratory, and bone marrow histological criteria for primary\n        myelofibrosis as defined by WHO diagnostic criteria as follows:\n\n        WHO diagnostic criteria for PMF18 Proposed Criteria for PMF Major Criteria\n\n          1. Presence of megakaryocyte proliferation and atypia, usually accompanied by either\n             reticulin and/or collagen fibrosis, or, in the absence of significant reticulin\n             fibrosis, the megakaryocyte changes must be accompanied by an increased bone marrow\n             cellularity characterized by granulocytic proliferation and often decreased\n             erythropoiesis (ie. prefibrotic cellular-phase disease)\n\n          2. Not meeting WHO criteria for PV, CML. MDS, or other myeloid neoplasm\n\n          3. Demonstration of JAK2617V>F or other clonal marker (e.g. MPL515W>L/K), or in the\n             absence of a clonal marker, no evidence of bone marrow fibrosis due to underlying\n             inflammatory or other neoplastic disease\n\n        Minor Criteria\n\n          1. Leukoerythroblastosis\n\n          2. increase in serum LDH\n\n          3. Anemia\n\n          4. Palpable splenomegaly\n\n               -  Patients must have Low or Intermediate 1 stage of disease as defined by\n                  International Working Group (IWG) risk stratification of primary myelofibrosis\n                  in the dynamic international prognostic scoring system (DIPSS). In addition,\n                  they must show some active hematopoiesism with a cellularity of at least 15%,\n                  irrespective of the degree of reticulin and/or collagen fibrosis as defined by\n                  Manoharan criteria49.\n\n               -  Patients should NOT have had prior therapy for primary myelofibrosis. This\n                  includes treatment with cytoreductive drugs (Hydroxyurea), immunomodulatory\n                  drugs (thalidomide, lenalidomide, pomalidomide), JAK2 inhibitors, or other\n                  therapies specifically for myelofibrosis. If they received these classes of\n                  drugs for indications other than PMF, treatment should be discontinued at least\n                  6 weeks prior to randomization.\n\n               -  ECOG performance status < 2\n\n               -  Patients must have normal organ and marrow function as defined below:\n\n                    -  WBC \u2265 3,000/microL\n\n                    -  ANC \u2265 1,500/microL\n\n                    -  platelets \u2265 100,000//microL\n\n                    -  total bilirubin within normal limits\n\n                    -  AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X upper limit of normal\n\n                    -  Creatinine Clearance \u2265 50 ml/min\n\n               -  The effects of peg-IFN\u03b1-2b on the developing human fetus at the recommended\n                  therapeutic dose are unknown.  For this reason, women of child-bearing potential\n                  and men must agree to use adequate contraception (hormonal or barrier method of\n                  birth control; abstinence) prior to study entry and for the duration of study\n                  participation.  Should a woman become pregnant or suspect she is pregnant while\n                  participating in this study, she should inform her treating physician\n                  immediately.\n\n               -  Ability to understand and the willingness to sign a written informed consent\n                  document.\n\n        Exclusion Criteria\n\n          -  Patients who have had chemotherapy or radiotherapy within 6 weeks prior to entering\n             the study or those who have not recovered from adverse events due to agents\n             administered more than 6 weeks earlier.\n\n          -  Patients with Intermediate 2 or High risk stage of disease as defined by\n             International Working Group (IWG) risk stratification of primary myelofibrosis in the\n             dynamic international prognostic scoring system (DIPSS) and/or bone marrow biopsy\n             showing less than 15% cellularity in the presence +2 or more reticulin fibrosis (by\n             Manoharan criteria)49, collagen fibrosis, or osteosclerosis.\n\n          -  Patients may not be receiving any other investigational agents.\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to peg-IFN\u03b1-2b\n\n          -  Other Exclusion Criteria\n\n               -  Female patients who are pregnant or breast feeding\n\n               -  History of depression or active treatment for depression\n\n               -  History of non-compliance to medical regimens\n\n               -  History of autoimmune diseases\n\n               -  History of hypothyroidism or hyperthyroidism\n\n               -  Clinical evidence of neuropathy\n\n          -  Uncontrolled illness including, but not limited to, ongoing or active infection,\n             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,\n             or psychiatric illness/social situations that would limit compliance with study\n             requirements.\n\n          -  Pregnant and lactating women are excluded from the study because the risks to an\n             unborn fetus or potential risks in nursing infants are unknown."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758588", 
            "org_study_id": "1202012178"
        }, 
        "intervention": {
            "arm_group_label": "Peginterferon alfa-2a", 
            "description": "50 mcg subcutaneous injection once per week", 
            "intervention_name": "Peginterferon alfa-2a", 
            "intervention_type": "Drug", 
            "other_name": "PEGINTRON, Interferon alfa, IFN\u03b1-2b"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Peginterferon alfa-2a", 
                "Peginterferon alfa-2b", 
                "Reaferon"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Primary myelofibrosis", 
            "PMF"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "wilena.s.session@emory.edu", 
                    "last_name": "Wilena Session", 
                    "phone": "404-778-5319"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University Hospital"
                }, 
                "investigator": {
                    "last_name": "Elliott Winton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rub9018@med.cornell.edu", 
                    "last_name": "Ruth Baumann, R.N.", 
                    "phone": "212-746-4882"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Weill Medial College of Cornell Universiy"
                }, 
                "investigator": [
                    {
                        "last_name": "Richard T Silver, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ellen K Ritchie, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Gail Roboz, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Eric Feldman, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis", 
        "overall_contact": {
            "email": "rtsilve@med.cornell.edu", 
            "last_name": "Richard T Silver, M.D.", 
            "phone": "646-962-2273"
        }, 
        "overall_official": {
            "affiliation": "Weill Medical College of Cornell University", 
            "last_name": "Richard T Silver, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Improved clinical status is defined as clinical improvement (CI) in the response criteria of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and is evaluated by blood and bone marrow tests performed every 4 weeks for one year.", 
            "measure": "Evidence of improved clinical status", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758588"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Survival will be assessed at one year from time of study entry.", 
            "measure": "Progression free survival and overall survival", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "source": "Weill Medical College of Cornell University", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Weill Medical College of Cornell University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}